I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

Presentation of Cantargia’s report for the second quarter of 2022

August 30th, 3.00 PM CEST

To Audiocast

Cantargia R&D Day on nadunolimab featuring Prof Van Cutsem and Dr Paz-Ares

To Webcast

Panel discussion business development

To Panel discussion

Cantargia in a panel discussion on how to build a successful biotech company

Panel discussion (in Swedish)

”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Göran Forsberg
CEO Cantargia